Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

How we approach patient evaluation for hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 45, pages 1259–1268 (2010)Cite this article

Subjects

Abstract

The evaluation of patients for hematopoietic stem cell transplantation is a complex process. The decision to recommend transplantation is not simply dependent on patient diagnosis; instead it is a specialized analytic decision process intricately dependent on a number of variables including patient age, performance status, medical comorbidities, family support structure, socioeconomic viability and motivation to participate in self-care, to name a few. The process of pre-transplant patient evaluation has substantial variability across different transplant centers, owing to lack of formal published guidelines. This review summarizes the process of pre-transplant patient evaluation and workup, and aims to describe components of a well-organized and evidenced-based patient selection process for SCT

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826.

    Article  CAS  Google Scholar 

  2. Blume KG, Amylon MD . The evaluation and counseling of candidates for hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas’ Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing: Malden, MA, 2004, pp 449–462.

    Google Scholar 

  3. http://www.medicalcenter.osu.edu/patientcare/healthcare_services/blood_disorders/bone_marrow_transplantation/Pages/index.aspx.

  4. de la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93: 735–740.

    Article  CAS  Google Scholar 

  5. Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757–3763.

    Article  Google Scholar 

  6. Ganti AK, Lee SJ, Vose JM, Devetten MP, Bociek RG, Armitage JO et al. Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning. J Clin Oncol 2007; 25: 5643–5648.

    Article  Google Scholar 

  7. Chatterjee R, Kottaridis PD . Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies. Bone Marrow Transplant 2002; 30: 629–635.

    Article  CAS  Google Scholar 

  8. Carter A, Robison LL, Francisco L, Smith D, Grant M, Baker KS et al. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the bone marrow transplant survivor study. Bone Marrow Transplant 2006; 37: 1023–1029.

    Article  CAS  Google Scholar 

  9. Hammond C, Abrams JR, Syrjala KL . Fertility and risk factors for elevated infertility concern in 10-year hematopoietic cell transplant survivors and case-matched controls. J Clin Oncol 2007; 25: 3511–3517.

    Article  Google Scholar 

  10. Schmidt KL, Andersen CY, Loft A, Byskov AG, Ernst E, Andersen AN . Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod 2005; 20: 3539–3546.

    Article  CAS  Google Scholar 

  11. Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L et al. Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. Bone Marrow Transplant 2003; 32: 433–436.

    Article  CAS  Google Scholar 

  12. Sloan JM, Ballen K . SCT in Jehovah's Witnesses: the bloodless transplant. Bone Marrow Transplant 2008; 41: 837–844.

    Article  CAS  Google Scholar 

  13. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316–2323.

    Article  CAS  Google Scholar 

  14. Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant 2006; 12: 61–67.

    Article  Google Scholar 

  15. Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2009; 15: 547–553.

    Article  Google Scholar 

  16. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700–708.

    Article  CAS  Google Scholar 

  17. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385–400.

    Article  Google Scholar 

  18. Michallet M, Thomas X, Vernant JP, Kuentz M, Socie G, Esperou-Bourdeau H et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 26: 1157–1163.

    Article  CAS  Google Scholar 

  19. Lee SJ, Joffe S, Artz AS, Champlin RE, Davies SM, Jagasia M et al. Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol 2008; 26: 2162–2170.

    Article  Google Scholar 

  20. Lee SJ, Fairclough D, Antin JH, Weeks JC . Discrepancies between patient and physician estimates for the success of stem cell transplantation. JAMA 2001; 285: 1034–1038.

    Article  CAS  Google Scholar 

  21. Cahn JY, Labopin M, Schattenberg A, Reiffers J, Willemze R, Zittoun R et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1997; 11: 416–419.

    Article  CAS  Google Scholar 

  22. Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto (GIMEMA) Leukemia Cooperative Groups. Bone Marrow Transplant 1996; 17: 993–1001.

    CAS  Google Scholar 

  23. Ringden O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993; 270: 57–60.

    Article  CAS  Google Scholar 

  24. Wildes TM, Augustin KM, Sempek D, Zhang QJ, Vij R, Dipersio JF et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 840–846.

    Article  CAS  Google Scholar 

  25. Yen KT, Lee AS, Krowka MJ, Burger CD . Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med 2004; 25: 189–201.

    Article  Google Scholar 

  26. Yoshihara S, Yanik G, Cooke KR, Mineishi S . Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 749–759.

    Article  Google Scholar 

  27. Cooke KR, Yanik G . Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease? Bone Marrow Transplant 2004; 34: 753–765.

    Article  CAS  Google Scholar 

  28. Crawford SW, Fisher L . Predictive value of pulmonary function tests before marrow transplantation. Chest 1992; 101: 1257–1264.

    Article  CAS  Google Scholar 

  29. Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 1261–1269.

    Article  Google Scholar 

  30. Singh AK, Karimpour SE, Savani BN, Guion P, Hope AJ, Mansueti JR et al. Pretransplant pulmonary function tests predict risk of mortality following fractionated total body irradiation and allogeneic peripheral blood stem cell transplant. Int J Radiat Oncol Biol Phys 2006; 66: 520–527.

    Article  Google Scholar 

  31. Savani BN, Montero A, Wu C, Nlonda N, Read E, Dunbar C et al. Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 223–230.

    Article  Google Scholar 

  32. Marks DI, Ballen K, Logan BR, Wang Z, Sobocinski KA, Bacigalupo A et al. The effect of smoking on allogeneic transplant outcomes. Biol Blood Marrow Transplant 2009; 15: 1277–1287.

    Article  CAS  Google Scholar 

  33. Murdych T, Weisdorf DJ . Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997. Bone Marrow Transplant 2001; 28: 283–287.

    Article  CAS  Google Scholar 

  34. Fujimaki K, Maruta A, Yoshida M, Sakai R, Tanabe J, Koharazawa H et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001; 27: 307–310.

    Article  CAS  Google Scholar 

  35. Zangari M, Henzlova MJ, Ahmad S, Scigliano E, Isola L, Platnik J et al. Predictive value of left ventricular ejection fraction in stem cell transplantation. Bone Marrow Transplant 1999; 23: 917–920.

    Article  CAS  Google Scholar 

  36. Bearman SI, Petersen FB, Schor RA, Denney JD, Fisher LD, Appelbaum FR et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 1990; 5: 173–177.

    CAS  PubMed  Google Scholar 

  37. Jain B, Floreani AA, Anderson JR, Vose JM, Robbins RA, Rennard SI et al. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. The University of Nebraska Medical Center Bone Marrow Transplantation Pulmonary Study Group. Bone Marrow Transplant 1996; 17: 561–568.

    CAS  PubMed  Google Scholar 

  38. Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transplant 2009; 15: 1265–1270.

    Article  Google Scholar 

  39. Nakamae H, Hino M, Akahori M, Terada Y, Yamane T, Ohta K et al. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol 2004; 76: 1–7.

    Article  Google Scholar 

  40. Akahori M, Nakamae H, Hino M, Yamane T, Hayashi T, Ohta K et al. Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue. Bone Marrow Transplant 2003; 31: 585–590.

    Article  CAS  Google Scholar 

  41. Hidalgo JD, Krone R, Rich MW, Blum K, Adkins D, Fan MY et al. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant 2004; 34: 615–619.

    Article  CAS  Google Scholar 

  42. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  Google Scholar 

  43. Majhail NS, Lazarus HM, Burns LJ . Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008; 41: 997–1003.

    Article  CAS  Google Scholar 

  44. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586–4588.

    Article  CAS  Google Scholar 

  45. Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009; 146: 310–316.

    Article  CAS  Google Scholar 

  46. Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R et al. Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transplant 2008; 14: 1239–1244.

    Article  Google Scholar 

  47. Mahindra A, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S et al. Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation. Bone Marrow Transplant 2009; 44: 767–768.

    Article  CAS  Google Scholar 

  48. Navarro WH, Loberiza FR, Bajorunaite R, van Besien K, Vose JM, Lazarus HM et al. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 541–551.

    Article  Google Scholar 

  49. Kersting S, Hene RJ, Koomans HA, Verdonck LF . Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1169–1175.

    Article  Google Scholar 

  50. Kersting S, Dorp SV, Theobald M, Verdonck LF . Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant 2008; 14: 125–131.

    Article  CAS  Google Scholar 

  51. Hahn T, Rondeau C, Shaukat A, Jupudy V, Miller A, Alam AR et al. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 2003; 32: 405–410.

    Article  CAS  Google Scholar 

  52. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  Google Scholar 

  53. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L et al. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1094–1099.

    Article  CAS  Google Scholar 

  54. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823–828.

    Article  CAS  Google Scholar 

  55. Hamaguchi M, Yamada H, Gondo H, Takemoto Y, Morishima Y, Kodera Y . Retrospective study on the impact of hepatitis B and hepatitis C virus infection on hematopoietic stem cell transplantation in Japan. Int J Hematol 2002; 75: 324–331.

    Article  Google Scholar 

  56. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM . Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1049–1059.

    Article  Google Scholar 

  57. Liang R . How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147–3153.

    Article  CAS  Google Scholar 

  58. Ramos CA, Saliba RM, de Padua L, Khorshid O, Shpall EJ, Giralt S et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009; 94: 249–257.

    Article  Google Scholar 

  59. Balsalobre P, Diez-Martin JL, Re A, Michieli M, Ribera JM, Canals C et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009; 27: 2192–2198.

    Article  Google Scholar 

  60. Krishnan A, Molina A, Zaia J, Nademanee A, Kogut N, Rosenthal J et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001; 98: 3857–3859.

    Article  CAS  Google Scholar 

  61. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114: 1306–1313.

    Article  CAS  Google Scholar 

  62. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008; 14: 59–66.

    Article  CAS  Google Scholar 

  63. Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE et al. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 864–871.

    Article  Google Scholar 

  64. Hamadani M, Devine SM . Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. Blood 2009; 114: 2564–2566.

    Article  CAS  Google Scholar 

  65. Woolfrey AE, Malhotra U, Harrington RD, McNevin J, Manley TJ, Riddell SR et al. Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation. Blood 2008; 112: 3484–3487.

    Article  CAS  Google Scholar 

  66. IDSA Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. Available from: http://www.cdc.gov/mmwr/PDF/rr/rr4910.pdf.(Accessed on 21 February 2010).

  67. Heslop HE . How I treat EBV lymphoproliferation. Blood 2009; 114: 4002–4008.

    Article  CAS  Google Scholar 

  68. Fukuda T, Boeckh M, Guthrie KA, Mattson DK, Owens S, Wald A et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494–503.

    Article  Google Scholar 

  69. Barker GJ . Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer 1999; 7: 17–20.

    Article  CAS  Google Scholar 

  70. Akintoye SO, Brennan MT, Graber CJ, McKinney BE, Rams TE, Barrett AJ et al. A retrospective investigation of advanced periodontal disease as a risk factor for septicemia in hematopoietic stem cell and bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94: 581–588.

    Article  Google Scholar 

  71. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  Google Scholar 

  72. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 2008; 19: 1166–1171.

    Article  CAS  Google Scholar 

  73. Andorsky DJ, Loberiza FR, Lee SJ . Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation. Bone Marrow Transplant 2006; 37: 889–895.

    Article  CAS  Google Scholar 

  74. Heinonen H, Volin L, Zevon MA, Uutela A, Barrick C, Ruutu T . Stress among allogeneic bone marrow transplantation patients. Patient Educ Couns 2005; 56: 62–71.

    Article  Google Scholar 

  75. Molassiotis A, van den Akker OB, Boughton BJ . Perceived social support, family environment and psychosocial recovery in bone marrow transplant long-term survivors. Soc Sci Med 1997; 44: 317–325.

    Article  CAS  Google Scholar 

  76. Meehan KR, Fitzmaurice T, Root L, Kimtis E, Patchett L, Hill J . The financial requirements and time commitments of caregivers for autologous stem cell transplant recipients. J Support Oncol 2006; 4: 187–190.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, The Osborn Blood and Marrow Transplantation Program, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA

    M Hamadani & M Craig

  2. Department of Medicine, Division of Hematology and Oncology, Medical College of Georgia, Augusta, GA, USA

    F T Awan

  3. Department of Medicine, Blood and Marrow Transplantation Program, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

    S M Devine

Authors
  1. M Hamadani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Craig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F T Awan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S M Devine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Hamadani.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamadani, M., Craig, M., Awan, F. et al. How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant 45, 1259–1268 (2010). https://doi.org/10.1038/bmt.2010.94

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.94

Keywords

This article is cited by

Search

Advanced search

Quick links